Limitations, agreements, and source contact

Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer · Source last updated 2018-02-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

lgedeon@gogstats.org

organization

NRG Oncology

phone

716-845-1169

title

Linda Gedeon for Michael Sill, PhD.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice